Ebola Vaccine from Glaxo Passes Early Trials

A possible Ebola vaccine under development by GlaxoSmithKline PLC GSK, +0.12% GSK, +0.52% and various U.S. government health agencies has shown positive results in a phase-1 trial, according to findings published Wednesday.

The trial involves human volunteers and is mostly meant to assess any possible side effects, Reuters reported. A White House statement released later in the day congratulated the National Institutes of Health on the success, saying the candidate treatment “has shown initial promise to prevent the spread of the Ebola virus infection.”

The early results were published in the New England Journal of Medicine. American depository shares of Glaxo closed flat Wednesday, but they rose 0.5% after hours.

Source: MarketWatch